SubsidieMeestersMinimally invasive reliAble Glucose monitoring in Intensive Care
GlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months.
Projectdetails
Introduction
9 of 10 intensive care unit (ICU) patients get elevated glucose levels because of their critical illness. Clinical trials prove that better glucose control could save thousands of lives and millions of euros for hospitals. Surprisingly, no continuous glucose monitor (CGM) is available for ICU patients, as solutions developed for diabetics don't work in the ICU.
Technology Overview
GlucoSet has a novel, patented technology for glucose monitoring. This enables, for the first time, reliable, minimally invasive, real-time monitoring of glucose in ICU patients.
Market Validation
4 of 5 EU ICU physicians say our product would be "very valuable" in their ICU and believe it will improve outcomes in their ICU. Additionally, 9 of 10 ICU managers say they are willing to pay for use in a large share of their patients on launch.
Product Development
A demo version of the product has been tested in patients with excellent results (TRL6).
Project Goals
This project aims to:
- Make the product ready for CE-mark (TRL8) in 25 months.
- Validate clinical benefits.
- Scale up (TRL9).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.026.500 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 31-1-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- GLUCOSET ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Advanced Remote Continuous patient Health mANaGemEnt SoLutionCheckpointcardio aims to revolutionize patient monitoring by establishing a 24/7 remote observation center using AI and wearables to enhance care for critically ill and chronic disease patients. | EIC Accelerator | € 2.436.000 | 2023 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Revolutionizing remote care of chronic disease patients – an interoperable and smart monitoring platformThe HumanITcare platform is an AI-driven solution that integrates data from various medical devices into EHRs, reducing patient visits by 40% and enhancing chronic disease management in Europe. | EIC Accelerator | € 2.438.800 | 2022 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
Advanced Remote Continuous patient Health mANaGemEnt SoLution
Checkpointcardio aims to revolutionize patient monitoring by establishing a 24/7 remote observation center using AI and wearables to enhance care for critically ill and chronic disease patients.
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Revolutionizing remote care of chronic disease patients – an interoperable and smart monitoring platform
The HumanITcare platform is an AI-driven solution that integrates data from various medical devices into EHRs, reducing patient visits by 40% and enhancing chronic disease management in Europe.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
GlucoMoveIQHet project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg. | Mkb-innovati... | € 20.000 | 2024 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensingGLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications. | EIC Transition | € 2.194.210 | 2022 | Details |
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes managementFAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions. | ERC Proof of... | € 150.000 | 2022 | Details |
AFIDIHet project ontwikkelt een betaalbare, minimaal invasieve CGM-sensor voor diabetespatiënten, die data veilig beheert en artsen toegang geeft, ter verbetering van zorg en vroegtijdige detectie van vaatlijden. | Mkb-innovati... | € 344.962 | 2023 | Details |
GlucoMoveIQ
Het project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensing
GLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications.
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes management
FAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions.
AFIDI
Het project ontwikkelt een betaalbare, minimaal invasieve CGM-sensor voor diabetespatiënten, die data veilig beheert en artsen toegang geeft, ter verbetering van zorg en vroegtijdige detectie van vaatlijden.